GHRP-6 vs GHRH (1–44)
Both GHRP-6 and GHRH (1–44) are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
GHRP-6
Evidence BGrowth Hormone Releasing Peptide 6
An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.
View full GHRP-6 profile →GHRH (1–44)
Evidence AGrowth Hormone Releasing Hormone, full sequence
The full 44-amino-acid GHRH sequence. The natural pituitary stimulus for GH release. Largely supplanted in clinical use by sermorelin/tesamorelin but remains a research and diagnostic tool.
View full GHRH (1–44) profile →Side-by-Side
| Attribute | GHRP-6 | GHRH (1–44) |
|---|---|---|
| Evidence Grade | B | A |
| FDA Status | Not FDA-approved — research compound | FDA-approved (Geref) historically as diagnostic GH stimulant; current US availability limited |
| Typical Dose | 100–300 mcg, 1–3 times daily (subcutaneous) | 1 mcg/kg IV (diagnostic test) |
| Clinics Indexed | 64 | 22 |
| Categories | growth-hormone, appetite | growth-hormone |
Key reported benefits — GHRP-6
- ✓GH release
- ✓Appetite stimulation
- ✓Cytoprotection
Key reported benefits — GHRH (1–44)
- ✓Endogenous GH stimulation
- ✓Diagnostic GH testing
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.